Bevacizumab-induced regression of anaplastic meningioma.
M J A
MJA
Puchner
Institute of Neuropathology, Evangelisches Krankenhaus Bielefeld, Bielefeld.
V H
VH
Hans
Department of Neurosurgery, Klinikum Vest GmbH-Knappschaftskrankenhaus Recklinghausen, Recklinghausen.
A
A
Harati
Department of Neurosurgery, Klinikum Vest GmbH-Knappschaftskrankenhaus Recklinghausen, Recklinghausen.
F
F
Lohmann
Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
M
M
Glas
Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany. Electronic address: ulrich.herrlinger@ukb.uni-bonn.de.
U
U
Herrlinger
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008577:Meningeal Neoplasms / Q000188:drug therapy*; D008579:Meningioma / Q000188:drug therapy*; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab